Spondyloarthritis

Bimekizumab Meets Primary and Secondary Endpoints for Treating Axial Spondyloarthritis

January 18, 2022

Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.

Jessica Walsh, MD: Treatment Satisfaction in Patients With Axial Spondyloarthritis

December 09, 2021

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

Secukinumab Improves Spinal Pain in Patients With Axial Spondyloarthritis

October 26, 2021

Chronic back pain, a common symptom of axial spondyloarthritis that increases disease burden and reduces quality of life, may be improved by subcutaneous injection of secukinumab 150 mg or 300 mg.

Upadacitinib Meets Primary and Most Ranked Secondary Endpoints in 2 Phase 3 Clinical Trials

October 08, 2021

Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Higher Disease Burden Seen in Women With Axial Spondyloarthritis

October 07, 2021

Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.

Ixekizumab Improves Fatigue in Patients With Non-Radiographic Axial Spondyloarthritis

October 05, 2021

“Many patients with axial spondyloarthritis who receive treatment still experience disease-related burdens in different aspects of health-related quality of life,” investigators stated.

Patients With Axial Spondyloarthritis Less Likely to Engage in Physical Activity

August 31, 2021

"Physical activity and exercise have been shown to improve general well-being and reduce cardiovascular disease risk in the general population," investigators stated. "Despite these recommendations, studies show that levels of PA are reduced among patients with axial spondyloarthritis.”